Treatment of the Surgical Infection Caused Pseudomonas Aeruginosa in Experiment


Cite item

Full Text

Abstract

The purpose of the study By morphological methods to estimate results of specific bacteriophage use for treatment of the experimental pneumonia caused Pseudomonas Aeruginosa. Materials and methods The changes of rat lungs, liver and spleen after bacteriophage application for treatment of the pneumonia caused Pseudomonas Aeruginosa were studied by method of light microscopy. Results and their discussion It was revealed that specific phagetherapy leads to disappearance of signs of respiratory insufficiency, the general intoxication, the pneumonia and sepsis phenomena, the increase in survival rate of animals. However, in the lungs after treatment there were signs of formation of abscessis, in liver - dystrophic changes of hepatocytes, and in spleen - hypertrophy and hyperplasia of lymphoid nodules. These complications, which can as well as be pneumonia consequences and phage use, demand working out and application of specific measures of preventive maintenance and treatment. Conclusion Survival of animals as a result of only a phagetherapy of the acute septic pneumonia caused by Pseudomonas aeruginosa, without application of antibacterial drugs, even in the presence of various complications, certainly, is positive result. Further researches for specifica-tion of a dosage, ways of application, indications and contraindications, complications of bacteriophage use for treatment of surgical infections are required

About the authors

The Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Branch, 8 Akademika
Lavrent'eva Ave., Novosibirsk, 630090, Russian Federation

Author for correspondence.
Email: author@vestnik-surgery.com
Ph.D., Student of the Institute of Chemical Biology and Fundamental Medicine of the SB RAS

The Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Branch, 8 Akademika
Lavrent'eva Ave., Novosibirsk, 630090, Russian Federation

Email: author@vestnik-surgery.com
Candidate of Biological Sciences, Senior Researcher of the Laboratory of Microbiology, Institute of Chemical Biology and Fundamental Medicine of the SB RAS

The Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Branch, 8 Akademika
Lavrent'eva Ave., Novosibirsk, 630090, Russian Federation

Email: imai@mail.ru
MD, Professor, Senior Researcher of the Laboratory of Stem Cells, Institute of Chemical Biology and Fundamental Medicine of the SB RAS

References

  1. Azzali G., Arcari M.L., Caldara G.F. "Rezhim"
  2. ehkstravazacii limfocitov cherez VGE v PB
  3. i ee rol' v normal'nyh samonavedeniya i vospalenie [The "mode" of
  4. lymphocyte extravasation through HEV of Peyer's patches
  5. and its role in normal homing and inflammation.] Microvasc.
  6. Res. 2008; 75: 2: 227-237.
  7. Barrow P.A., Soothill J.S. Bakteriofag terapii i
  8. profilaktika: vozrozhdenie i vozobnovlenie ocenku
  9. potencial. [Bacteriophage therapy and
  10. prophylaxis: rediscovery and renewed assessment of the
  11. potential.] Trends Microbiol. 1997; 5: 7: 268-271.
  12. Kucharewicz-Krukowska A., Slopek S. Immunogennyj ehffekt
  13. bakteriofaga u pacientov, podvergshihsya fagovoj terapii [Immunogenic effect
  14. of bacteriophage in patients subjected to phage therapy.]
  15. Arch. Immunol. Ther. Exp. (Warsz). 1987; 35: 5: 553-561.
  16. Kutter E., Vos de D., Gvasalia G. et al. Fagovoj terapii v
  17. klinicheskoj praktike: lechenie infekcij cheloveka [Phage therapy in
  18. clinical practice: treatment of human infections.] Curr.
  19. Pharm. Biotechnol. 2010; 1: 1: 69-86.
  20. Lederberg J. Men'she bloh ... do beskonechnosti: lechebnyj
  21. bakteriofag perevozhd' [Smaller fleas ... ad infinitum: therapeutic
  22. bacteriophage redux.] Proc. Natl. Acad. Sci. USA. 1996; 93:
  23. : 3167-3168.
  24. Levin B.R., Bull J.J. Populyacionnaya i ehvolyucionnaya dinamika
  25. fagoterapii [Population and evolutionary dynamics
  26. of phage therapy.] Nat. Rev. Microbiol. 2004; 2: 2: 166-173.
  27. Merril C.R., Biswas B., Carlton R. et al. Dlitel'no cirkuliruyushchih
  28. bakteriofag v kachestve antibakterial'nyh agentov [Long-circulating
  29. bacteriophage as antibacterial agents.] Proc. Natl. Acad.
  30. Sci. USA. 1996; 93: 8: 3188-3192.
  31. O'Hanlon T.P., Lawless O.J., Katzin W.E. et al. Ogranichenie
  32. i obobshchenie modeli TKR beta-cepi ehkspressii genov v
  33. kapsuly implantata silikonovye grudi i udalennyh uchastkov tkani
  34. vospalenie. [Restricted
  35. and shared patterns of TCR beta-chain gene expression in
  36. silicone breast implant capsules and remote sites of tissue
  37. inflammation.] J. Autoimmun. 2000; 14: 4: 283-293.
  38. Pirnay J.P., Vos de D., Verbeken G. et al. V fagovoj terapii
  39. paradigma: pret-a-porte ili syur-izmeryaem? [The phagetherapy
  40. paradigm: prêt-à-porter or sur-mesure?] Pharm. Res. 2011;
  41. : 4: 934-937.
  42. Radetsky P. Vozvrashchenie horoshego virusa [Return of the Good Virus.] Discover. 1996; 17:
  43. -58.
  44. Slopek S., Durlakowa I., Weber-Dabrowska B. et al. Rezul'taty bakteriofaga dlya lecheniya gnojnyh bakterial'nyh
  45. infekcij. I. Obshchaya ocenka rezul'tatov
  46. [Results of bacteriophage treatment of suppurative bacterial
  47. infections. I. General evaluation of the results.] Arch.
  48. Immunol. Ther. Exp. (Warsz). 1983; 31: 3: 267-291.
  49. Slopek S., Kucharewicz-Krukowska A., Weber-Dabrowska
  50. B., Dabrowski M. Rezul'taty bakteriofagovogo lecheniya
  51. gnojnyh bakterial'nyh infekcij. 4. Ocenka
  52. rezul'tatov, poluchennyh v 370 sluchayah [Results of bacteriophage treatment of
  53. suppurative bacterial infections. IV. Evaluation of the
  54. results obtained in 370 cases.] Arch. Immunol. Ther. Exp.
  55. (Warsz). 1985; 33: 2: 219-240.
  56. Slopek S., Weber-Dabrowska B., Dabrowski M.,
  57. Kucharewicz-Krukowska A. Rezul'taty bakteriofag
  58. lechenie gnojnyh bakterial'nyh infekcij v gody
  59. -1986 [Results of bacteriophage
  60. treatment of suppurative bacterial infections in the years
  61. -1986;] Arch. Immunol. Ther. Exp. (Warsz). 1987; 35:
  62. : 569-583.
  63. Soothill J.S. Bakteriofag predotvrashchaet razrushenie kozhi
  64. privivkoj ot sinegnojnoj palochki [Bacteriophage prevents destruction of skin
  65. grafts by Pseudomonas aeruginosa.] Burns. 1994; 20: 3:
  66. -211.
  67. Soothill J.S. Lechenie ehksperimental'nyh infekcij u myshej
  68. s bakteriofagami [Treatment of experimental infections of mice
  69. with bacteriophages.] J. Med. Microbiol. 1992; 37: 4: 258-
  71. Soothill J.S., Morton D.B., Ahmad A. V HID50
  72. (pereohlazhdenie, vyzyvayushchee doza 50): al'ternativa LD50
  73. dlya izmereniya bakterial'noj virulentnosti [The HID50
  74. (hypothermia-inducing dose 50): an alternative to the LD50
  75. for measurement of bacterial virulence.] Int. J. Exp. Pathol.
  76. ; 90: 2, 1992; 73: 1: 95-98.
  77. Weber-Dabrowska B., Dabrowski M., Slopek S. Issledovaniya po
  78. proniknovenie bakteriofaga u pacientov, podvergshihsya faga
  79. terapiya [Studies on
  80. bacteriophage penetration in patients subjected to phage
  81. therapy.] Arch. Immunol. Ther. Exp. (Warsz). 1987; 35: 5:
  82. -568.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies